Phase II study of MP-376 for the treatment of non-cystic fibrosis bronchiectasis (BE)
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Levofloxacin (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- 25 Oct 2016 This trial was planned by Raptor Pharmaceutical Corp. The company has now been acquired by Horizon Pharma plc, according to a Horizon Pharma plc media release.
- 29 Feb 2016 New trial record
- 25 Feb 2016 According to Raptor Pharmaceutical Corp media release, the company intends to initiate this trial in this year (2016).